SSL Secured
All Major Cards Accepted
Apple Pay & Google Pay
2-Day Shipping Available
The File
Most brands send a discount code.
We send the papers.
Every active we use, the exact amount of it, and the published work behind it — including the studies that did not go our way. Published in full, free to read, no email required. Every study below links to the journal that published it.
Verified against source documents · Last reviewed 11 August 2026
Download the PDF — 4 pagesHow to read this
Three questions, asked of every ingredient
1
What is it, exactly? The branded active, its standardisation, and the amount in one serving — not a proprietary blend.
2
Was it studied in people? And if so, was it this material at this amount, or something adjacent?
3
What did the study actually find? Including the endpoints that missed significance.
Supplement
VFlex — Q-Actin®
Five published human studies of the active. This is the one product in the range we sell on human evidence, so here is all of it — the misses included. Every row links to the paper. We would rather you read it than read us summarising it.
| Study | Design | n | Length | Result, as reported |
|---|---|---|---|---|
| Nash 2018PMC6207263 | RCT, active comparator — no placebo arm | 122 | 180 days | WOMAC −70.3% within-group |
| Nash 2023PubMed 36748212 | RCT, placebo-controlled, 3-arm | 101 | 180 days | Significant, dose-dependent |
| Hausenblas 2025 (Cureus)PMC12486685 | RCT, double-blind, placebo | 81 | 60 days | WOMAC interaction p = 0.13 — not significant |
| Hausenblas 2025 (HSR)PMC12239509 | Same cohort — mood and sleep | 80 | 60 days | BPI Pain Interference p = 0.05 |
| Lloyd 2025PMC12104766 | RCT, double-blind, placebo, gummy format | 56 | 12 weeks | Nine-Hole Peg Test p = 0.011 · PSQI sleep p = 0.020 |
What we have to tell you about these.
- The two Hausenblas 2025 papers report one cohort, not two. Counting them as two studies would overstate the record — so the honest count is five papers, four cohorts.
- The Cureus paper's primary endpoint missed significance (p = 0.13). We publish it because leaving it out would make the other four look better than they are.
- Nash 2018 had no placebo arm, and dosed 10 mg twice daily rather than 20 mg once. Same total, different schedule.
- Our once-daily evening 20 mg matches the schedule used in Hausenblas 2025 and Lloyd 2025.
- No adverse events were reported across all five trials.
Patents: US 9,326,977 B2 · US 9,717,718 B2 · US 2022/0288049 A1 · EP 2766019 B1. Q-Actin® is a registered trademark of IminoTech, Inc. IP held by Phytoquest Limited. GRAS status is self-affirmed by the supplier — there is no FDA notice number.
Supplement
MitoV+ — MitoPrime®
There is no human trial of MitoPrime® itself. Every published study used L-ergothioneine from a different supplier. And the doses that produced results were 8–25 mg a day. We use 5 mg.
So we make no efficacy claim for this product. We sell it on what we can prove: the identity and purity of the material, verified per batch. If you see a brand claiming energy or longevity outcomes for ergothioneine, ask them for the trial at their dose.
One more, because it is the least convenient fact we hold: the name MitoV+ implies mitochondria, but the case that antioxidant action is ergothioneine's principal function in the living body is explicitly called weak by the field's own senior authors — Halliwell, Tang & Cheah 2023PubMed 36623925. We are not going to quietly drop that because we chose the name.
The intervention literature for the molecule — different material, mostly higher doses, listed so you can judge the gap yourself rather than take our word for it:
| Study | n | Dose | Length | Result |
|---|---|---|---|---|
| Cheah 2017PubMed 27488221 | 45 | 5 or 25 mg/d | 7 d + 35 d follow-up | Absorbed and retained — under 4% leaves in urine. Damage biomarkers mostly non-significant. A pharmacokinetic study, not an RCT |
| Yau 2024PubMed 39544014 | 19 | 25 mg, 3×/week | 12 months | Placebo-controlled. Verbal learning improved; neurofilament light stabilised. A pilot — nineteen people |
| Okumura 2025PMC12138820 | 100 | 8 mg/d | 16 weeks | Sleep (OSA-MA Factor V) p = 0.007 |
| Zajac 2025Flinders University | 147 | 10 or 25 mg/d | 16 weeks | Plasma 3–16× (p < 0.001); cognitive effects limited |
What that table does not say — and the study that is missing from it.
- Cheah 2017 is the only study run at our dose, and at 5 mg it found nothing significant. What it did establish is that 5 mg is absorbed and held — under 4% leaves in urine. Getting into the body is not the same as doing something in it, and we are not going to blur the two.
- The one trial built to answer this has never reported. ErgMS, at the University of Leeds, was designed to compare placebo against 5 mg and 30 mg over 12 weeks — those two doses chosen precisely because they are what the industry sells. The protocolPubMed 34715934 was published in 2021 and registered as ISRCTN25890011. No results paper has appeared. We searched the authors directly rather than assume.
- We have left the skin studies out on purpose. Ergothioneine trials reporting firmer skin and fewer wrinkles do exist. They run at 30 mg a day, they use other companies' material, one tested a mushroom extract rather than the pure molecule, and one is not yet peer-reviewed — and MitoV+ is not sold for skin. Borrowing them would be the same move we refuse for Vioni+ below. A rule you drop when it would flatter you is not a rule.
- We do not cite our supplier's own dossier. MitoPrime's manufacturer publishes skin results built on a patent application, an unpublished project and cell-culture work. None peer-reviewed. A manufacturer measuring its own product is not evidence; it is marketing with footnotes.
One large observational dataset exists, and it is the strongest human signal ergothioneine has. It is not a supplement trial, and we are not going to present it as one:
| Study | Design | n | Follow-up | Result |
|---|---|---|---|---|
| Smith 2020 (Heart)PubMed 31672783 | Prospective cohort — observational | 3,236 | 21.4 years (median) | Higher blood ergothioneine tracked with lower coronary disease (HR 0.85), cardiovascular mortality (HR 0.79) and all-cause mortality (HR 0.86) |
Read that one carefully, because the industry routinely does not. It measured ergothioneine already in people's blood, arriving from food — mushrooms above all. Nobody was given a supplement. People with more of it in their blood also ate better, and the study cannot separate the two. It is a good reason to find the question interesting. It is not a reason to believe a 5 mg gummy lengthens anyone's life, and we will not imply that it is.
GRAS self-affirmed by NNB Nutrition, 2 January 2026. Note: GRN 000734 belongs to ErgoActive®, a different material — it is not MitoPrime's notice, and we do not cite it as one.
Supplement
Vioni+ — Ioniplex®
No published human clinical trial of Ioniplex® exists. Not few — none. The only human study sits unpublished inside a patent (US 11,103,001), and its between-group result was not statistically significant; the patent itself calls it only "trendwise significantly greater".
There is no link in this section because there is nothing to link to. That is the finding.
We are not going to borrow shilajit's research to cover it. Shilajit, CHD-FA and humic acids are different materials — citing them here would be the exact trick this file exists to refuse. Vioni+ is sold as a standardised mineral foundation, verified per batch, and nothing more.
Two things we correct about our own earlier material: the fulvic figure is ≥77%, not "90%+"; and the extraction patent US 9,044,417 expired in 2023 — the live patents cover composition, and patents are not evidence of efficacy in any case.
Live patents: US 8,709,497 B2 (to 2028) · US 8,927,031 B2 (to 2030) · US 11,103,001 B2. Sodium is 174.70 mg per gummy and appears on the Supplement Facts panel.
Skincare
The three serums
Skincare is regulated as cosmetics, so everything below refers to the appearance of skin. Each serum's full ingredient list is published on its product page — no proprietary blends there either.
Cellular Clarity
Delentigo™ — at the concentration used in its published work
Four pigment-actives rather than one. For the appearance of uneven tone and dark spots.
Contains soy.
Cellular Radiance
NovoRetin™ — at 1.5× the studied concentration
More than the amount used in its studies, stated plainly rather than implied. For the appearance of smoothness and surface renewal.
Cellular Renewal
PhytoCellTec™ apple fruit cell culture · polynucleotide complex
We make no evidence claim for this serum. It is sold on its named actives and its formulation. That is a deliberate decision, not an oversight.
Contains a fish-derived ingredient. Not vegan.
A note we would rather you heard from us: every branded active in these serums — PhytoCellTec™, MossCellTec™, Delentigo™ — has zero PubMed-indexed human trials. The ingredients in them with real published evidence are the ordinary ones: glycerin, sodium hyaluronate, arbutin, liquiritin. That is the inverse of how this category is usually sold.
What this file contains
Four pages, and none of them flattering by accident
- The published studies behind each named active, linked so you can read the source yourself
- The standardisation and assay method for every branded ingredient
- The exact amount in one serving — never a proprietary blend
- The gaps — every place the evidence is thinner than the category pretends
No summary written by us standing in for the source. If a claim on this site cannot survive you reading the paper behind it, the claim should not be there — and we would rather you find that out before you buy than after.
Download the PDF†These statements have not been evaluated by the Food and Drug Administration. Supplement products are not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before use if you are pregnant, nursing, or taking medication.
Skincare: for external use only. Avoid the eye area. Patch test 48 hours before first use. Discontinue use if irritation occurs. Results refer to the appearance of skin.
Links point to the journals and repositories that host each paper. We do not host copies of third-party research — the source is the source.